Watertown, MA – According to filings with the U.S. Securities and Exchange Commission, SQZ Biotechnologies is raising $70,203,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Armon Sharei played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SQZ Biotechnologies
At SQZ we believe that cell therapies can revolutionize the way we treat diseases. The SQZ cell therapy platform can be the foundation of a new generation of therapeutics. By enabling engineering of almost any function into any cell type, the SQZ platform overcomes fundamental barriers in the field and enables the creation of previously infeasible cell therapies. Our current focus is on creating high-impact therapies for patients in the fields of oncology, infectious disease, and auto-immunity. Ultimately, SQZ has the potential to create therapies addressing a broad range of diseases.

To learn more about SQZ Biotechnologies, visit http://sqzbiotech.com/

Contact:
Armon Sharei, Chief Executive Officer
617-898-8824
sharei.armon@sqzbiotech.com
https://www.linkedin.com/in/armon-sharei-09862726/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved